Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Author
Mohammed, ArianaReaders/Advisors
Middleton, ElizabethTerm and Year
Spring 2021Date Published
2021
Metadata
Show full item recordAbstract
The most effective and most used antibiotics for treating infections are known as beta-lactams. Unfortunately, more and more bacteria are developing different ways to fight against these antibiotics. The most common causes of resistance involve the creation of β-lactamase, which allows hydrolysis of the β-lactam ring, which results in the inactivation of the drug. A way around this is using β-lactamase inhibitors like clavulanic acid, sulbactam and tazobactam in combination with β-lactams for treatment. But, there is still bacterial resistance that occurs with combination therapy and it keeps evolving, which results in people developing immunity to these medications. As a result, scientists are looking to find broad-spectrum β-lactamase inhibitors that successfully fight β-lactamases. (Eiamphungporn et al., 2018)Collections